Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / Alpha-melanocyte stimulating hormone (α-MSH) is a pro-opiomelanocortin (POMC)-derived peptide involved in different neurological functions that also exerts anti-inflammatory effects, including in the central nervous system (CNS). Although inflammation has been implicated in seizures and epilepsy, no study has systematically investigated whether α-MSH modifies seizures. Therefore, in the current study we determined whether α-MSH alters pentylenetetrazol (PTZ)- and pilocarpine-induced seizures. Adult male Swiss mice were injected with α-MSH (1.66, 5 or 15 μg/3 μL, intracerebroventricular (i.c.v.) or systemic (0.1, 0.3 or 1 mg/kg, intraperitoneally (i.p.)). Five to sixty minutes after the injection of the peptide, animals were injected with PTZ (60 mg/kg, i.p.) or pilocarpine (370 mg/kg, i.p.). Latency to myoclonic jerks and tonic clonic seizures, number of seizure episodes, total time spent seizing and seizure intensity, assessed by the Racine and Meurs scales were recorded. Interleukin 1 beta (IL-1β) levels in the hippocampus were measured by a commercial enzyme-linked immunoabsorbent assay (ELISA). Neither intracerebroventricular (1.66, 5 or 15 μg/3 μL, i.c.v.) nor systemic (0.1, 0.3 or 1 mg/kg, i.p.) administration of α-MSH altered PTZ- and pilocarpine-induced seizures. IL-1β levels in the hippocampi were not altered by α-MSH, PTZ or pilocarpine. Although inflammation has been implicated in seizures and epilepsy and α-MSH is a potent antiinflammatory peptide, our results do not support a role for α-MSH in seizure control. / O hormônio alfa-estimulante dos melanócitos (α-MSH), é um peptídeo derivado da pró-opiomelanocortina (POMC) envolvido em diferentes funções neurológicas que também exercem efeitos antiinflamatórios, incluindo o sistema nervoso central (SNC). Embora inflamação tenha sido relacionada com convulsão e epilepsia, nenhum estudo tem investigado se o α-MSH sistemicamente altera crises. Portanto, no presente estudo verificou-se se α-MSH altera as convulsões induzidas por pentilenotetrazol (PTZ) e pilocarpina. Camundongos machos Swiss receberam α-MSH (1.66, 5 ou 15 μg/3 μL, intracerebroventricular (i.c.v.) or sistêmico (0.1, 0.3 ou 1 mg/kg, intraperitoneal (i.p.)). Cinco a sessenta minutos após a injeção do peptídeo, os animais receberam PTZ (60 mg/kg, i.p.) ou pilocarpina (370 mg/kg, i.p.). Latência para mioclonia e convulsão tônico-clônica, número de episódios convulsivos duração e gravidade das convulsão, foram avaliadas pela escala de Racine e Meurs. Os níveis de IL-1β no hipocampo foram medidos através de um ensaio imunoenzimático (ELISA). Nem administração de α-MSH intracerebroventricular (1.66, 5 ou 15 μg/3 μL) nem sistêmica (0.1, 0.3 ou 1 mg/kg) alterou as convulsões induzidas por PTZ e pilocarpina. α-MSH, PTZ ou pilocarpina não alteraram os níveis de IL-1β no hipocampo. Embora a inflamação tem sido implicada em convulsões e epilepsia e α-MSH é um peptídeo antiinflamatório potente, os nossos resultados não suportam um papel para α-MSH no controle das convulsões.

Le mélanome est un cancer de la peau très agressif. Microphthalmia-associated transcription factor (MITF) est un facteur de transcription clé contrôlant le développement de la lignée mélanocytaire, ainsi que la prolifération et l’invasion des cellules de mélanome. Pour mieux comprendre les fonctions de MITF, nous avons identifié ses cofacteurs impliques dans la régulation de la transcription. Nous avons montré que le complexe de remodelage de la chromatine NURF interagit avec MITF. Ma thèse a consisté à élucider le rôle de NURF dans le mélanome et les mélanocytes. La perte de BPTF, la principale sous-unité de ce complexe, induit un arrêt de la prolifération et une entrée en senescence des cellules de mélanome. Nous avons montré que BPTF et MITF coopèrent pour réguler l’expression de gènes impliqués dans la prolifération and invasion suggérant que BPTF et un cofacteur de MITF. De façon inattendue, l’inactivation de BPTF spécifiquement dans les mélanocytes entraine la perte progressive et totale de la pigmentation du pelage en raison de l’incapacité des cellules souches mélanocytaire à produire une descendance fonctionnelle. C’est la première fois que l’interaction fonctionnelle entre NURF et MITF est démontrée in vitro, complétée par des observations phénotypique uniques in vivo, contribuant à la compréhension de la biologie des mélanocytes et du mélanome. / Melanoma is a highly aggressive form of skin cancer. Microphthalmia-associated transcription factor (MITF) isa key regulator of development of the melanocyte lineage and proliferation and invasion of melanoma cells.To further elucidate the functions of MITF, we identified factors co-regulating transcription with MITF. We identified the NURF chromatin-remodeling complex as MITF interactor. My thesis aims to elucidate the role of NURF in melanoma and melanocytes. Loss of BPTF, the principal subunit of the complex, led to arrest of proliferation and entry into senescence of melanoma lines. We showed BPTF and MITF co-regulate genes involved in proliferation and invasion suggesting that BPTF acts as cofactor for MITF. Remarkably, the mouse model of melanocyte-specific BPTF ablation led to progressive and complete loss of coat pigmentation due to the inability of the melanocyte stem cells to produce functional progeny. This is the first report of NURF-MITF functional interaction in vitro, complemented with a unique in vivo phenotype, both adding to a general understanding of melanocyte and melanoma biology.

No / This study shows that prostaglandins in human FM55 melanoma cells and epidermal melanocytes are produced by COX-1. Prostaglandin production in FM55 melanoma cells was unrelated to that of melanin suggesting that the two processes can occur independently. ¿-Melanocyte stimulating hormone (¿-MSH), which had no effect on melanin production in FM55 cells, stimulated PGD2 production in these cells without affecting PGE2. While cAMP pathways may be involved in regulating PGD2 production, our results suggest that ¿-MSH acts independently of cAMP, possibly by regulating the activity of lipocalin-type PGD synthase. This ¿-MSH-mediated effect may be associated with its role as an immune modulator. / The Wellcome Trust

O hormônio alfa estimulador de melanócito (alfa-MSH) é um neuropeptídeo com atividade anti-inflamatória que apresenta efeitos benéficos em modelos experimentais de doenças autoimunes. Entretanto pouca atenção tem sido dada a seus efeitos no lúpus eritematoso sistêmico (LES). No presente estudo utilizou-se o tratamento com o super análogo NDP-MSH em modelo experimental de LES induzido por pristane. Grupos de camundongos fêmeas foram tratados diariamente com 1,25 mg/Kg de NDP-MSH ou solução salina por 180 dias. Foram avaliados os seguintes parâmetros séricos: isotipos de IgG, anticorpos antinucleares (FAN) e citocinas. A intensidade da artrite foi mensurada por graduação de edema e eritema. A função renal foi estimada por proteinúria e escore histopatológico. A expressão de IgG, alfa-SMA, iNOS, C3, CD3, MC1R, CRF e alfa-MSH glomerular foi quantificada por imunohistoquímica. Camundongos com LES apresentaram aumento de IgG, FAN, IL-6, IL-10 e TNFalfa, escore de artrite, disfunção renal e celularidade mesangial quando comparados aos animais controle normais. O tratamento dos animais LES com NDP-MSH reduziu os títulos de IgG1 e IgG2a (p < 0,05 e p < 0,001 respectivamente), bem como a incidência de FAN+ (p < 0,05). Níveis séricos de IL-6 e IL-10 foram abrandados e houve aumento dos níveis de TNFalfa (p < 0,05). O escore de artrite foi reduzido em 70% (p < 0,01). A proteinúria não foi afetada pelo tratamento, entretanto houve 50% de redução do grau de lesão glomerular (p < 0,05). A avaliação imunohistoquímica mostrou que o tratamento reduziu os depósitos de IgG e a expressão de alfa-SMA e iNOS glomerular (p < 0,01; p < 0,01 e p < 0,05 respectivamente). A expressão do receptor MC1R foi menor nos grupos LES, tratados ou não. A expressão de alfa-MSH e CRF estavam diminuídas somente no grupo tratado com NDP-MSH enquanto a expressão de C3 e CD3 não diferiu entre os grupos. Em conjunto nossos resultados sugerem, pela primeira vez, que a o tratamento com o análogo de alfa-MSH melhora a atividade da doença em modelo experimental de LES / Alpha-melanocyte stimulating hormone (alfa-MSH) is a neuropeptide with anti-inflammatory activity that has beneficial effects in experimental models of autoimmune diseases. However little attention has been paid to its effects on systemic lupus erythematosus (SLE). Herein we employed the treatment with the super analogue NDP-MSH in experimental SLE induced by pristane. Groups of female mice were treated daily with 1.25 mg/Kg of NDP-MSH (SLE-MSH) or saline for 180 days. The following parameters were evaluated: serum IgG isotypes, antinuclear antibodies (ANA) and cytokines. Arthritis was graded by edema and erythema in each paw. Renal function was estimated by proteinuria and histopathological score. The expression of IgG, alfa-SMA, iNOS, C3, CD3, MC1R, CRF and alfa-MSH was quantified by immunohistochemistry in glomerulus. SLE mice presented increased IgG levels, ANA, IL-6, IL-10 and TNFalfa, arthritis incidence, renal dysfunction and mesangial cellularity when compared with normal animals. Animals SLE-MSH presented reduction of IgG1 and IgG2a titles (p < 0.05 and p < 0.001 respectively), as well as the incidence of FAN+ (p < 0.05). The treatment reduced IL-6 and IL-10 serum levels and increase of TNFalfa levels (p < 0.05). Arthritis score was reduced in 70% in SLE-MSH animals (p < 0.01). Proteinuria was not affected by the treatment, however it was registered a 50% reduction of the glomerular lesion (p < 0.05). The immunohistochemical evaluation revealed reduced IgG deposits and glomerular expression of alfa-SMA and iNOS in SLE-MSH animals (p < 0.01, p < 0.01 and p < 0.05 vs.LES, respectively). MC1R was sub expressed in SLE animals, treated or not. The expression of alfa-MSH and CRF were impaired only in the SLE-MSH group. Taken together our results suggest for the first time that treatment with alfa-MSH analogue improve disease activity in an experimental model of SLE

Le mélanome est un cancer très agressif en raison de sa capacité rapide à former des métastases et de développer une résistance aux traitements existants.
 MITF (Micropthalmia-associated Transcription Factor) est un facteur de transcription clé à toutes les étapes de développement du lignage mélanocytaire et dans la physiopathologie du mélanome. Afin de comprendre les mécanismes impliqués dans la régulation de l’activité et de la stabilité de MITF, nous avons identifié ses partenaires protéiques parmi lesquels figurent de nombreuses sous-unités des complexes de remodelage de la chromatine ATP-dépendant PBAF et NURF. Ce travail caractérise le rôle et l’étendue de la coopération entre BRG1/PBAF et plusieurs facteurs de transcription clés tels que MITF et SOX10 dans le fonctionnement des cellules de mélanome, qui recrutent activement de BRG1 à la chromatine et contribuent ainsi à la mise en place de la signature épigénétique caractéristique des cellules de mélanome prolifératives. Par ailleurs, l’utilisation de différents modèles murins a permis de révéler in vivo la contribution fonctionnelle distincte mais complémentaire de ces deux complexes de remodelage associé à MITF aux cours de trois stades majeurs du lignage mélanocytaire : le développement embryonnaire des mélanocytes, leur différentiation ainsi que lors de l’initiation et la progression du mélanome. Ce travail contribue ainsi à une meilleure compréhension du fonctionnement biologique des mélanocytes, du mélanome et du remodelage de la chromatine chez les eucaryotes. / Malignant melanoma is the most deadly form of skin cancer due to its quick metastatic spread and the development of resistance to available treatments.
MITF (Micropthalmia-associated Transcription Factor) is a transcription factor and master regulator of melanocyte lineage development and melanoma physiopathology. In order to investigate the mechanisms involved in the regulation of MITF activity and stability, we identified its numerous partners by tandem affinity purification coupled to mass spectrometry, which include several subunits of the PBAF and NURF ATP-dependant chromatin remodelling complexes. The present work characterizes the role and extent of cooperation between BRG1/PBAF and several key transcription factors including MITF and SOX10 in melanoma cell function, that actively recruit BRG1 to chromatin to establish the epigenetic landscape of proliferative melanoma cells. Furthermore, using different mouse models we revealed the distinct but complementary functional contribution of these two MITF-associated chromatin remodelers in vivo at three majors stages of melanocyte lineage development: embryonic development of melanocytes, their differentiation and during melanomagenesis. Thus, this work contributes to a better understanding of processes regulating the biological function of melanocytes, melanoma and more widely chromatin remodelling events in eukaryotes.

O hormônio alfa estimulador de melanócito (alfa-MSH) é um neuropeptídeo com atividade anti-inflamatória que apresenta efeitos benéficos em modelos experimentais de doenças autoimunes. Entretanto pouca atenção tem sido dada a seus efeitos no lúpus eritematoso sistêmico (LES). No presente estudo utilizou-se o tratamento com o super análogo NDP-MSH em modelo experimental de LES induzido por pristane. Grupos de camundongos fêmeas foram tratados diariamente com 1,25 mg/Kg de NDP-MSH ou solução salina por 180 dias. Foram avaliados os seguintes parâmetros séricos: isotipos de IgG, anticorpos antinucleares (FAN) e citocinas. A intensidade da artrite foi mensurada por graduação de edema e eritema. A função renal foi estimada por proteinúria e escore histopatológico. A expressão de IgG, alfa-SMA, iNOS, C3, CD3, MC1R, CRF e alfa-MSH glomerular foi quantificada por imunohistoquímica. Camundongos com LES apresentaram aumento de IgG, FAN, IL-6, IL-10 e TNFalfa, escore de artrite, disfunção renal e celularidade mesangial quando comparados aos animais controle normais. O tratamento dos animais LES com NDP-MSH reduziu os títulos de IgG1 e IgG2a (p < 0,05 e p < 0,001 respectivamente), bem como a incidência de FAN+ (p < 0,05). Níveis séricos de IL-6 e IL-10 foram abrandados e houve aumento dos níveis de TNFalfa (p < 0,05). O escore de artrite foi reduzido em 70% (p < 0,01). A proteinúria não foi afetada pelo tratamento, entretanto houve 50% de redução do grau de lesão glomerular (p < 0,05). A avaliação imunohistoquímica mostrou que o tratamento reduziu os depósitos de IgG e a expressão de alfa-SMA e iNOS glomerular (p < 0,01; p < 0,01 e p < 0,05 respectivamente). A expressão do receptor MC1R foi menor nos grupos LES, tratados ou não. A expressão de alfa-MSH e CRF estavam diminuídas somente no grupo tratado com NDP-MSH enquanto a expressão de C3 e CD3 não diferiu entre os grupos. Em conjunto nossos resultados sugerem, pela primeira vez, que a o tratamento com o análogo de alfa-MSH melhora a atividade da doença em modelo experimental de LES / Alpha-melanocyte stimulating hormone (alfa-MSH) is a neuropeptide with anti-inflammatory activity that has beneficial effects in experimental models of autoimmune diseases. However little attention has been paid to its effects on systemic lupus erythematosus (SLE). Herein we employed the treatment with the super analogue NDP-MSH in experimental SLE induced by pristane. Groups of female mice were treated daily with 1.25 mg/Kg of NDP-MSH (SLE-MSH) or saline for 180 days. The following parameters were evaluated: serum IgG isotypes, antinuclear antibodies (ANA) and cytokines. Arthritis was graded by edema and erythema in each paw. Renal function was estimated by proteinuria and histopathological score. The expression of IgG, alfa-SMA, iNOS, C3, CD3, MC1R, CRF and alfa-MSH was quantified by immunohistochemistry in glomerulus. SLE mice presented increased IgG levels, ANA, IL-6, IL-10 and TNFalfa, arthritis incidence, renal dysfunction and mesangial cellularity when compared with normal animals. Animals SLE-MSH presented reduction of IgG1 and IgG2a titles (p < 0.05 and p < 0.001 respectively), as well as the incidence of FAN+ (p < 0.05). The treatment reduced IL-6 and IL-10 serum levels and increase of TNFalfa levels (p < 0.05). Arthritis score was reduced in 70% in SLE-MSH animals (p < 0.01). Proteinuria was not affected by the treatment, however it was registered a 50% reduction of the glomerular lesion (p < 0.05). The immunohistochemical evaluation revealed reduced IgG deposits and glomerular expression of alfa-SMA and iNOS in SLE-MSH animals (p < 0.01, p < 0.01 and p < 0.05 vs.LES, respectively). MC1R was sub expressed in SLE animals, treated or not. The expression of alfa-MSH and CRF were impaired only in the SLE-MSH group. Taken together our results suggest for the first time that treatment with alfa-MSH analogue improve disease activity in an experimental model of SLE

Pigmentation plays a protective role against damage caused by ultraviolet (UV) irradiation. Humans with fair skin and light hair have a higher susceptibility to UV-induced DNA damage that can lead to the development of skin cancers. The melanocytes found in the skin and hair follicles depend on different signaling molecules for their proper development and pigment production. α-Melanocyte Stimulating Hormone (α-msh) binds to the Melanocortin 1 receptor (Mc1r) to regulate pigment production and the switch between eumelanin and pheomelanin. Lethal yellow mice (Ay) overexpress the agouti signaling protein, which inhibits the binding of α-msh, resulting in a yellow coat color phenotype. Endothelin 3 (Edn3) encodes for a ligand involved in melanocyte development by regulating the differentiation, proliferation and migration of melanocyte precursors. A tetracycline inducible transgenic mouse in which Edn3 was placed under the keratin 5 promoter (K5-tTA;TRE-Edn3-lacZ) displays a hyperpigmentation phenotype due to the accumulation of melanocytes in the skin and an increase in hair pigment. Comparative analysis of dorsal hairs from Ay and Ay; K5-tTA;TRE-Edn3-lacZ mice using high performance liquid chromatography showed that transgenic Edn3 expression significantly increased both eumelanin and pheomelanin. No significant difference in the number of follicular melanocytes between Edn3 transgenic and non-transgenic mice was evidenced by immunofluorescence using an antibody against Tyrosinase related protein 1. Gene expression analysis of hair follicles showed that Edn3 upregulates the expression of melanogenic genes. Deactivation of transgenic Edn3 is possible with doxycycline (dox) treatment. To test if transgenic Edn3 expression is required to rescue and maintain a dark pigmentation phenotype in Ay mice, dox was administered during embryonic and postnatal development to manipulate transgenic Edn3 expression. Results showed that transgenic Edn3 expression is required to maintain a dark pigmentation phenotype after birth but is independent of a developmental requirement. Transgenic Edn3 expression in Mc1re/e mice also resulted in a darkened coat color. Our results indicate that the paracrine expression of Edn3 from keratinocytes is capable of generating and maintaining a dark coat color by the regulation of melanogenic genes independent of Mc1r signaling. The results of this study may open new approaches to the treatment of hypopigmentation disorders.

alpha-melanocyte stimulating hormone (alpha-MSH) is an important regulator of food intake, metabolic rate, and inflammation. Recently, alpha-MSH was shown to influence sympathetic activity and blood pressure regulation. In the present study, we investigated the cardiovascular effects of alpha-MSH in the nucleus tractus solitarii (NTS) of spontaneously hypertensive rats (SHR). Because nitric oxide (NO) is well-known to involve in central cardiovascular regulation, we elucidated the role of NO in the cardiovascular responses induced by alpha-MSH. In urethane-anesthetized SHR, unilateral microinjection of alpha-MSH (0.3-300 pmol) into the NTS produced dose-responsive depressor and bradycardic effects. The cardiovascular effects of alpha-MSH were abrogated by the antagonist of melanocortin receptor (MC3/4-R), SHU9119. Pretreatment with precursor of nitric oxide, L-arginine, enhanced the duration of alpha-MSH-mediated hypotensive effects, whereas prior application of L-NAME, a universal inhibitor of nitric oxide synthase (NOS), significantly attenuated the effects of alpha-MSH. Prior injection with inhibitor of inducible NOS, aminoguanidine, but not inhibitor of neuronal NOS, 7-nitroindazole, attenuated the hypotensive effect of alpha-MSH. In summary, these results indicated alpha-MSH induced depressor and bradycardic effects in the NTS of SHR. Besides, the hypotensive mechanism of alpha-MSH was mediated via MC4-R and involved with iNOS activation in the NTS of SHR.

Thesis (Ph.D.)--University of Florida, 2004. / Typescript. Title from title page of source document. Document formatted into pages; contains 142 pages. Includes Vita. Includes bibliographical references.

Recycling embosoms (REs) are transient intermediates of endosomal network, constantly generated from early/sorting endosomes (EEs/SEs). Conventionally, these organelles function in recycling of many growth/nutrient/signalling receptors from SEs to the cell surface and maintain the cellular homeostasis in all cell types. Recent studies have shown that REs slightly diverted their function in specialized cells such as melanocytes for the delivery of melanogenic cargo to a set of lysosome-related organelles (LROs) called melanosomes. However, it is unknown how melanocytes modulate the trafficking routes of REs towards the biogenesis of melanosomes. Any alterations in this process result in occulocutaneous albinism, commonly observed in autosomal recessive disorder, Hermansky-Pudlak Syndrome (HPS). HPS is caused by mutations in nine genes in human and fifteen genes in mouse and the protein products of these genes were grouped in multiple endosomal protein complexes; BLOC (Biogenesis of Lysosome-related Organelles Complex)-1, -2, -3, AP (Adaptor Protein)-3 and HOPS (homotypic fusion and protein sorting). Studies from our laboratory and others have shown that REs deliver the melanin-synthesizing enzymes to melanosome in BLOC-1 and BLOC-2 dependent manner. On the other side, studies in fibroblasts have shown that the adaptor AP-1 and microtubule-dependent motor, KIF13A also regulates the formation of REs. In these studies, it was proposed that AP-1 binds to the cargo tails and interacts with motor KIF13A to generate the RE tubules, where BLOC-1 initiates the biogenesis. Nevertheless, the mechanism behind the biogenesis of REs and how these molecules synergistically control these processes is largely unknown. Additionally, the role of BLOC-2 in REs biogenesis never been implicated. Here we have attempted to study the mechanism of RE biogenesis and their role in pigment granule formation using HeLa and mouse melanocytes as model systems. In general, Rab GTPases (Rabs) regulate the several process of membrane trafficking including cargo sorting, membrane domain organization, tethering and fusion. We hypothesized that the biogenesis of RE is also regulated by one of the endosome localized Rab GTPases. Our RNAi screening against Rabs involved in regulating the RE length/number showed Rab22A as a potential candidate. Thus, we aim to study the role of Rab22A in RE biogenesis and its regulation in melanocyte pigmentation. The current study entitled as “Understanding the role of Rab22A in recycling endosome biogenesis and melanocyte pigmentation” is divided into five chapters. Chapter-I outlines the review of literature on cell biology of intracellular organelles such as endocytic network and melanosomes. Chapter-II details the experimental procedures used in the study. Chapter-III to Chapter-V describes the results and discussion. Chapter-III: Identification of endosomal Rab GTPases required for the dynamics of recycling endosomes Endosomal Rabs are known to regulate various functions such as vesicle biogenesis, transport, tethering and fusion, but their role in generation of tubulo-vesicular carriers of endocytic system, REs is unknown. It has been shown that REs possibly derived from EEs/SEs and characterized by the association/localization of multiple proteins such as transferrin receptor (TfR), SNARE STX13, Rab11 and motor KIF13A. In this study, we have used YFP-KIF13A as a marker to label the REs. YFP-KIF13A in HeLa cells localized to long tubular structures throughout the cell and also to the clusters of peripheral endosomes. To identify the endosomal Rabs that regulate the RE dynamics (both length and number), we have transfected the HeLa cells with shRNA against endosomal Rabs such as Rab4A, Rab5A, Rab5B, Rab5C, Rab7A, Rab9A, Rab11A, Rab14A and Rab22A. Post transfection and shRNA selection, cells were transfected with YFP-KIF13A, analyzed and quantified the RE dynamics using ImageJ. Here, we have measured two parameters for the identification of Rab/s that potentially regulates the REs biogenesis: first, average number of tubules per cell and second, average length of tubules per cell. These studies identified Rab22A as a potential candidate, depletion of this Rab affects both number and average length of KIF13A-positive tubules. As described above, REs deliver several melanocyte specific cargoes to melanosomes in melanocytes. However, the function of Rab22A in controlling these transport steps to melanosome/its biogenesis or pigmentation has not been addressed. Thus, we have studied the mechanism of Rab22A in RE biogenesis and its role in pigmentation in the following sections. Chapter-IV: Characterization of Rab22A function in regulating the recycling endosomes Initially, we tested whether Rab22A localizes to the REs. Our co-expression studies show that Rab22A localizes to KIF13A- or STX13-positive RE compartments in HeLa or melanocytes, respectively. In general, Rab GTPases mediate their function through cycling between GTP (membrane bound) and GDP (cytosol) bound state. These states can be achieved by point mutation of active site residues in the protein. We have generated Rab22A constitutive active mutant (Rab22AQ64L, defective in GTP hydrolysis) and dominant negative mutant (Rab22AS19N, defective in GTP binding) to understand the role of Rab22A in regulating REs. Interestingly, overexpression of Rab22AQ64L mutant in HeLa cells increases the average number of KIF13A-positive REs relative to the wild-type Rab22A (Rab22AWT). As predicted, overexpression of Rab22AS19N mutant reduces the number as well as length of RE tubules relative to the control HeLa cells. Consistent to these studies, Rab22A-knockdown did not affect the endogenous KIF13A protein levels or its recruitment to endosomes, however recycling of TfR (measured through Tf-Alexa 594) was significantly affected in these cells. These studies suggest that Rab22A possibly regulates the formation or function of REs. Likewise, overexpression of Rab22AQ64L and Rab22AS19N mutants in melanocytes resulted in reduction of total melanin content in the cells. To confirm these results, we have performed immunofluorescence microscopy (IFM) analysis, which showed Rab22AQ64L localized to the enlarged vacuolar structures, positive for melanosomal cargo TYRP1 (tyrosinase-related protein 1), whereas Rab22AS19N localized to the cytosol. Further, Rab22A depletion in melanocytes causes the hypopigmentation in the cells concurrently reduces the stability of TYRP1 but not other melanocyte specific proteins, indicating a role for Rab22A in regulating TYRP1 transport to melanosomes. Altogether, our studies suggests that Rab22A regulates the TfR recycling in HeLa cells and TYRP1 transport in melanocytes by controlling the RE dynamics. Chapter-V: Molecular mechanism of recycling endosome biogenesis: a role for Rab22A Rabs perform their function by recruiting specific effector/s to the membrane upon Rab activation. It is unknown, how Rab22A regulates REs through its effectors. We hypothesize that Rab22A may regulate the recruitment and function of BLOC-1 and BLOC-2 complexes during RE formation. To validate these hypothesis, we carried out the knockdown of individual BLOC-1 and -2 subunits (destabilize the entire complex) separately in HeLa and studied the dynamics of RE through YFP-KIF13A expression. As expected, the length and number of KIF13A-postive tubules were significantly reduced in both BLOC-1- and BLOC-2-deficient HeLa cells and was phenocopying the Rab22A knockdown cells. Moreover, subcellular fractionation in HeLa, co-fractionated Rab22A with BLOC-1 (Muted) or BLOC-2 (HPS6) subunits along with KIF13A. Additionally, endogenous subunit levels of BLOC-1 and BLOC-2 were moderately reduced in Rab22A knockdown HeLa cells. Consistent to these results, recycling kinetics of Transferrin (Tf) was altered in Rab22A depleted cells as similar to BLOC-1- or BLOC-2-deficient cells as reported earlier. Likewise, Rab22A knockdown in melanocytes affected STX13-positive tubules and also the stability of endogenous BLOC-1 subunit, Pallidin, suggesting that Rab22A possibly works with BLOC-1 and BLOC-2 independent of cell types. To understand the regulation among these molecules, we overexpressed Rab22A in BLOC-1-deficient cells and analyzed the cells for BLOC-1-deficient rescue phenotypes such as pigmentation and cargo localization. However, Rab22A could not compensate the BLOC-1 function, suggesting that Rab22A possibly functions upstream of BLOC-1. Our subcellular and membrane associated fractionation studies of homogenates depleted with Rab22A, BLOC-1 and BLOC-2 showed that subunit levels of BLOC-1 and BLOC-2 in the membrane pool were significantly reduced upon Rab22A depletion compared to control cells. However, membrane association of Rab22A in BLOC-1 deficient cells was not affected. Further, our biochemical interaction studies showed that Rab22A interacts physically with BLOC-1 and BLOC-2 subunits as well as with KIF13A. Thus, these studies indicate that Rab22A possibly recruits and interacts with BLOC-1 and BLOC-2 for the generation of REs. We have summarized the study by proposing a model wherein Rab22A localizes to the limiting membrane of endosomes that are positive for KIF13A and then recruits and associates with BLOC-1 and BLOC-2 complexes which subsequently pulled by KIF13A for the generation of RE tubules.